Table of Contents

company-logo

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

89bio Dividend Announcement

• 89bio does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on 89bio dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

89bio Dividend History

89bio Dividend Yield

89bio current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing 89bio stock? Use our calculator to estimate your expected dividend yield:

89bio Financial Ratios

P/E ratio-0.37
PEG ratio-0.00
P/B ratio0.28
ROE-59.58%
Payout ratio-0.00%
Current ratio11.66
Quick ratio11.66
Cash Ratio2.34

89bio Dividend FAQ

Does 89bio stock pay dividends?
89bio does not currently pay dividends to its shareholders.
Has 89bio ever paid a dividend?
No, 89bio has no a history of paying dividends to its shareholders. 89bio is not known for its dividend payments.
Why doesn't 89bio pay dividends?
There are several potential reasons why 89bio would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will 89bio ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While 89bio has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is 89bio a dividend aristocrat?
89bio is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is 89bio a dividend king?
89bio is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is 89bio a dividend stock?
No, 89bio is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy 89bio stocks?
To buy 89bio you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy 89bio stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.